PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Aug 29, 2022

Keywords

ClinConnect Summary

The PREOPANC-4 study is focused on improving the treatment of locally advanced pancreatic cancer (LAPC) in the Netherlands. This clinical trial is evaluating an international standard of care that combines surgery with chemotherapy, aiming to enhance patient safety and ensure treatments are centered around what patients need. The project involves training healthcare professionals at top medical centers to provide the best possible care for patients with this condition.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of LAPC that has not worsened after receiving specific chemotherapy treatments for at least four months. Unfortunately, those with cancer that has spread to other parts of the body or has significant involvement of major blood vessels may not be eligible. If you qualify and decide to join, you can expect to receive cutting-edge care and be part of a program designed to improve outcomes for patients with this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Pathology-confirmed (LAPC)\*
• • CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\[m\]FOLFIRINOX / gemcitabine-nab-paclitaxel).
• Exclusion Criteria:
• • Metastatic pancreatic cancer prior to induction chemotherapy.
• • According to the Dutch Pancreatic Cancer Group (DPCG) definition: \>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either \>270 degrees or occlusion.